+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 167 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and early effectiveness of SAR445877, a new drug given alone or with other cancer treatments, in adults aged 18 and older who have advanced solid tumors that cannot be surgically removed or have spread. This Phase 12 open-label study includes participants who have limited or no standard treatment options, aiming to find the best dose and assess how well SAR445877 works in different combinations. The study has two parts Part 1 focuses on gradually increasing doses of SAR445877 given intravenously every one or two weeks to find safe and effective doses alone or with other therapies like cetuximab, ADG126, or bevacizumab. Part 2 expands to multiple groups testing SAR445877 at recommended doses, either alone or combined with these other anticancer drugs, in various cancer types such as melanoma, non-small cell lung cancer, colorectal, gastric, and liver cancers. Participants undergo a screening period of up to 28 days before starting treatment, which continues until the cancer progresses, unacceptable side effects occur, or other reasons require stopping. After treatment ends, there is a follow-up period to monitor outcomes until disease progression, new therapy, death, or withdrawal. Throughout the study, researchers collect safety data, tumor response measures, drug levels in the body, and immune responses to evaluate the effects of SAR445877 and combinations for up to two years.

Age: 18Years +All GendersPhase 1Phase 2
22 locations
L

Actively Recruiting

Researchers are studying the long-term safety of ciltacabtagene autoleucel cilta-cel, a CAR-T therapy targeting B-cell maturation antigen in patients previously treated for multiple myeloma. The goal is to collect data on delayed side effects and better understand the long-term risks associated with cilta-cel treatment. This study is a phase 4 trial sponsored by Janssen Research & Development, LLC. Participants in this study do not receive any new treatment. Instead, the study monitors individuals who had previously received cilta-cel in company-sponsored clinical trials. The study is divided into two phases the first five years after the last cilta-cel dose, and years six to fifteen after that dose. Follow-up evaluations are conducted at least once per year to check for any delayed adverse events. During the study, participants undergo safety assessments including reviews of adverse events, laboratory tests, physical and neurological examinations. Researchers track outcomes such as new malignancies, neurological or autoimmune disorders, serious infections, and other serious adverse events over a period of up to 15 years. This long-term follow-up helps characterize the safety profile of cilta-cel after treatment completion.

Age: 18Years +All GendersPhase 4
50 locations
T

Actively Recruiting

Researchers are conducting a prospective, longitudinal, non-interventional multicenter study involving participants with head and neck squamous cell carcinoma HNSCC. The study focuses on patients with metastatic or unresectable recurrent HNSCC who are planned to receive first-line immunotherapy or combination therapy. This study aims to explore molecular biomarkers from tissue and blood samples to better understand prognostic and predictive markers, and to guide future biomarker research. Participants will not receive any experimental treatment as this is an observational study. Instead, molecular profiling will be done using tumor tissue and blood samples collected during their standard of care. The study plans to include up to 500 participants with tumors located in the pharynx, larynx, oral cavity, or oropharynx. There is no intervention, and participants will continue their planned first-line anti-PD1 or PDL1 therapy or combination treatment. Throughout the five-year study period, researchers will collect longitudinal blood samples and diagnostic or progression biopsy samples to examine changes in DNA, RNA, immune markers, and circulating tumor DNA ctDNA. These assessments aim to understand real-world outcomes, resistance mechanisms, and evaluate ctDNA as a response biomarker. Participants will provide informed consent, and their compliance with study procedures, including blood sample collection, will be monitored.

Age: 18Years +All Genders
32 locations
A

Actively Recruiting

Researchers are studying the use of unlicensed cryopreserved cord blood units CBUs for transplantation in both children and adults with blood cancers and other related disorders. This observational study involves patients with hematologic malignancies and various inherited and acquired disorders affecting the blood and immune system. The main goal is to monitor how well neutrophil recovery occurs after transplantation using these unlicensed CBUs in multiple institutions. Participants receive unlicensed cryopreserved CBUs as part of their transplant treatment. The study includes patients of any age receiving these CBUs for approved indications. The protocol focuses on the access and distribution of these unlicensed units rather than a specific treatment intervention. The study gathers data from recipients who receive these CBUs, tracking outcomes after transplantation. Participants are monitored for neutrophil recovery at 60 and 100 days after transplant, defined by a neutrophil count of at least 500mm3. Researchers also collect information on infection transmission, infusion reactions, survival rates at one year, and incidence of acute and chronic graft versus host disease. Platelet recovery is also evaluated. Safety and efficacy outcomes are followed over time to better understand the effects of unlicensed CBUs in this patient population.

All AgesAll Genders
142 locations
S

Actively Recruiting

Researchers are evaluating a new treatment approach for adults aged 18 to 75 years with newly diagnosed acute myeloid leukemia AML that has specific genetic changes in the NPM1, MLLKMT2A, or NUP98 genes. This phase Ib trial aims to find the best dose and assess the safety of the drug revumenib SNDX-5613 when combined with standard chemotherapy drugs daunorubicin and cytarabine. The study focuses on patients who can tolerate intensive chemotherapy and have untreated AML. Participants receive revumenib orally twice daily alongside daunorubicin given intravenously for 1 to 3 days and cytarabine given as a continuous infusion or intermittent intravenous infusion depending on the treatment phase. Treatment includes an induction phase, possible re-induction for persistent disease, and consolidation cycles repeated every 42 days up to three times if tolerated. During treatment, patients undergo heart function scans, bone marrow biopsies, and blood tests at scheduled times to monitor response and safety. Throughout the study, patients are closely monitored through clinical assessments, including pharmacokinetic studies of revumenib and evaluations of leukemia cell response. After completing treatment, participants are followed for up to two years or until relapse or death. Researchers measure the recommended dose for further study, complete response rates, and other important outcomes such as measurable residual disease and potential biomarkers related to treatment response.

Age: 18Years - 75YearsAll GendersPhase 1
23 locations
O

Actively Recruiting

Researchers are evaluating zanidatamab for the treatment of adults with previously treated solid tumors that show high levels of HER2 protein IHC 3 overexpression. This phase 2, open-label study focuses on participants whose cancers have progressed despite prior systemic treatments and who have no confirmed beneficial treatment options left. Participants receive zanidatamab administered by intravenous infusion. The study includes participants with various HER2-expressing solid tumors, excluding biliary tract cancers. Some cohorts allow prior HER2-targeted therapy, while others do not. Treatment continues with monitoring for up to 2.5 years to evaluate response and safety. During the study, participants undergo regular assessments including tumor evaluations by independent central review and investigator assessment using RECIST 1.1 criteria. Researchers monitor objective response rates, duration and time to response, disease control, progression-free and overall survival, and treatment-emergent adverse events. Blood samples measure zanidatamab concentration and antibody development. Participants are followed for safety and treatment effects for up to 3.5 years.

Age: 18Years +All GendersPhase 2
42 locations
P

Actively Recruiting

Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
193 locations
S

Actively Recruiting

Researchers are evaluating drug combinations to prevent graft-versus-host disease GVHD in people who have received stem cell transplants from unrelated donors with different blood types. This platform protocol focuses on safety and effectiveness of post-transplant cyclophosphamide PTCy based GVHD prevention after mismatched unrelated donor hematopoietic cell transplants in patients with malignant blood diseases. The study compares new drug combinations to a standard treatment. Participants receive one of the drug combinations after transplant, including investigational arms named ACCEL-001 and ACCEL-002, or the shared comparator control group. Conditioning regimens vary and may include combinations of drugs such as busulfan, fludarabine, melphalan, cyclophosphamide, and total body irradiation before transplant. The donor stem cell graft infusion occurs on Day 0, followed by specific post-transplant medications like cyclophosphamide, tacrolimus, mycophenolate mofetil, abatacept, and ruxolitinib, with supportive care for infection prevention and other complications. During the study, participants have regular doctor visits for check-ups and routine tests, complete surveys on physical and emotional health, and provide blood and stool samples. Researchers monitor outcomes including graft-versus-host disease-free, relapse-free survival one year after transplant, infection rates, survival, graft failure, and immune recovery. Safety is closely tracked, including monitoring for cytokine release syndrome and infections. The study lasts for at least one year post-transplant, with detailed data collection on treatment response and side effects.

Age: 18Years - 66YearsAll GendersPhase 2
13 locations
R

Actively Recruiting

Researchers are evaluating treatments for patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms MPNs. This phase II trial compares ASTX727, a combination of cedazuridine and decitabine, given alone or combined with iadademstat. The study aims to assess how these treatments affect leukemia response rates and survival outcomes in patients who have not previously received certain DNA methyltransferase inhibitors. Patients are assigned to one of two groups. One group receives ASTX727 orally once daily on days 1 to 5 of each 28-day cycle. The other group receives the same ASTX727 schedule plus iadademstat orally on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Treatment continues until disease progression or unacceptable side effects occur. Throughout the trial, researchers collect blood, buccal swab, and bone marrow samples to study the disease and treatment effects. Participants have regular assessments including blood tests, bone marrow biopsies, and sample collections over the treatment period. After stopping treatment for reasons other than disease progression, they are followed every 3 months if they stop due to progression, follow-up occurs every 6 months. The main outcome measured is the acute leukemia response rate within 4 treatment cycles. Secondary outcomes include event-free survival, overall survival, and the rate of stem cell transplantation over two years.

Age: 18Years +All GendersPhase 2
32 locations
P

Actively Recruiting

Researchers are evaluating CTX112, an allogeneic CD19-directed chimeric antigen receptor CAR T cell immunotherapy, in adults with relapsed or refractory B-cell malignancies. This open-label, multicenter Phase 12 study aims to assess the safety and effectiveness of CTX112, which uses genetically modified T cells edited with CRISPR-Cas9 technology to target cancer cells. The study is sponsored by CRISPR Therapeutics AG and includes patients with various B-cell cancers such as lymphoma and leukemia. Participants receive CTX112 through an intravenous infusion after undergoing lymphodepleting chemotherapy to prepare their bodies. The Phase 1 portion focuses on dose escalation to evaluate safety and identify dose-limiting toxicities within 28 days after infusion. In Phase 2, the study expands to assess objective response rates over up to 60 months. The treatment involves only the CTX112 product administered by IV infusion. During the study, participants will be closely monitored for adverse events, treatment response, and disease progression through clinical assessments and laboratory tests. Researchers will measure outcomes such as duration of response, progression-free survival, and overall survival for up to five years following infusion. Female participants of childbearing potential and male participants must use contraception during the study and for one year afterward. The study excludes those with certain infections, prior transplants, CNS involvement, and other specific medical conditions to ensure participant safety.

Age: 18Years +All GendersPhase 1Phase 2
7 locations

1-10 of 167

1